--- title: "Arbutus Pharma | 10-Q: FY2026 Q1 Revenue: USD 179.13 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286252525.md" datetime: "2026-05-13T11:33:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286252525.md) - [en](https://longbridge.com/en/news/286252525.md) - [zh-HK](https://longbridge.com/zh-HK/news/286252525.md) --- # Arbutus Pharma | 10-Q: FY2026 Q1 Revenue: USD 179.13 M Revenue: As of FY2026 Q1, the actual value is USD 179.13 M. EPS: As of FY2026 Q1, the actual value is USD 0.87. EBIT: As of FY2026 Q1, the actual value is USD 168.11 M. Arbutus Biopharma Corporation operates as a single reportable segment, with all financial metrics reflecting the company’s overall performance for the three months ended March 31, 2026, compared to the same period in 2025 . #### Revenue - **Total Revenue**: Increased to $179.1 million in 2026 from $1.8 million in 2025 . - **Collaborations and Licenses**: Revenue from Acuitas Therapeutics, Inc. was $0.2 million in 2026, down from $0.5 million in 2025 . Revenue from Qilu Pharmaceutical Co., Ltd. was $0 in 2026, down from $0.8 million in 2025 . - **License Revenue from Genevant**: Recognized $178.7 million in 2026, compared to $0 in 2025 . - **Non-cash Royalty Revenue (Alnylam Pharmaceuticals, Inc.)**: Decreased to $0.2 million in 2026 from $0.4 million in 2025 . #### Operating Expenses - **Total Operating Expenses**: Decreased to $10.2 million in 2026 from $27.5 million in 2025 . - **Research and Development**: Decreased to $4.1 million in 2026 from $9.0 million in 2025 . - **General and Administrative**: Increased to $5.9 million in 2026 from $5.8 million in 2025 . - **Change in Fair Value of Contingent Consideration**: Increased to $0.2 million in 2026 from $0.3 million in 2025 . - **Restructuring Costs**: $0 in 2026, a significant decrease from $12.4 million in 2025 . #### Income (Loss) from Operations - **Income (Loss) from Operations**: Improved to $168.9 million income in 2026 from a -$25.7 million loss in 2025 . #### Other Income (Loss) - **Total Other Income**: Decreased to $0.8 million in 2026 from $1.2 million in 2025 . - **Interest Income**: Decreased to $0.8 million in 2026 from $1.2 million in 2025 . - **Interest Expense**: Decreased to -$0.02 million in 2026 from -$0.03 million in 2025 . - **Foreign Exchange (Loss) Gain**: -$0.01 million loss in 2026 compared to a $0.004 million gain in 2025 . #### Net Income (Loss) - **Net Income (Loss)**: Reported a net income of $169.7 million in 2026, a significant improvement from a net loss of -$24.5 million in 2025 . #### Cash Flow - **Net Cash Used in Operating Activities**: Decreased to -$8.1 million in 2026 from -$13.4 million in 2025 . - **Net Cash Provided by Investing Activities**: Decreased to $2.2 million in 2026 from $11.3 million in 2025 . - **Net Cash Provided by Financing Activities**: Increased to $11.6 million in 2026 from $2.8 million in 2025 . - **Cash and Cash Equivalents, End of Period**: $23.7 million as of March 31, 2026, compared to $37.1 million as of March 31, 2025 . #### Balance Sheet Highlights (as of March 31, 2026 vs. December 31, 2025) - **Cash and Cash Equivalents**: $23.7 million as of March 31, 2026, up from $18.0 million as of December 31, 2025 . - **Investments in Marketable Securities, Current**: $71.5 million as of March 31, 2026, down from $73.5 million as of December 31, 2025 . - **License Receivable from Genevant**: $178.7 million as of March 31, 2026, up from $0 as of December 31, 2025 . - **Total Current Assets**: $277.0 million as of March 31, 2026, up from $94.5 million as of December 31, 2025 . - **Total Stockholders’ Equity**: $260.2 million as of March 31, 2026, up from $76.6 million as of December 31, 2025 . - **Contingent Consideration Liability**: $8.6 million as of March 31, 2026, up from $8.4 million as of December 31, 2025 . - **Liability Related to Sale of Future Royalties**: $3.3 million as of March 31, 2026, down from $3.4 million as of December 31, 2025 . #### Unique Metrics - **Moderna Settlement Agreement**: Arbutus Biopharma Corporation expects to receive an estimated $178.7 million noncontingent lump sum payment from Moderna on or before July 8, 2026, with a potential additional contingent payment of $1.3 billion upon a favorable ruling in a limited appeal . - **OMERS Royalty Entitlement**: As of March 31, 2026, $26.7 million in royalties had been earned by OMERS out of a total of $30 million from the sale of future ONPATTRO royalties . - **Genevant Ownership**: Arbutus Biopharma Corporation owned approximately 16% of Genevant’s outstanding common equity as of March 31, 2026 . - **Restructuring**: The company implemented a 57% workforce reduction and discontinued in-house scientific research in March 2025, resulting in 18 employees as of March 31, 2026 . #### Future Outlook and Strategy Arbutus Biopharma Corporation anticipates having sufficient cash resources to fund operations for at least the next 12 months and is evaluating a return of capital to shareholders in Q3 2026 following the Moderna settlement payment . The company’s strategy prioritizes maximizing opportunities for its chronic hepatitis B development programs (imdusiran and AB-101) and defending its LNP technology intellectual property . Arbutus Biopharma Corporation expects to maintain its reduced net cash burn in 2026 due to organizational changes and ongoing cost management efforts . ### Related Stocks - [ABUS.US](https://longbridge.com/en/quote/ABUS.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO](https://longbridge.com/en/news/286643939.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md) - [Strides Pharma Q4FY26 results: Net profit jumps 51% to ₹129 crore](https://longbridge.com/en/news/286757182.md)